Adverse Cardiovascular Events Associated With Cyclin‐Dependent Kinase 4/6 Inhibitors in Patients With Metastatic Breast Cancer

Adverse Cardiovascular Events Associated With Cyclin‐Dependent Kinase 4/6 Inhibitors in Patients With Metastatic Breast Cancer

Background Cyclin‐dependent kinase (CDK) 4 and 6 inhibitors have significantly improved survival in patients with hormone receptor–positive metastatic breast cancer. There are few data regarding the epidemiology of cardiovascular adverse events (CVAEs) with these therapies. Methods and Results Using...

Full description

Bibliographic Details
Main Authors: Michael G. Fradley, Nam H. K. Nguyen, David Madnick, Yiqing Chen, Angela DeMichele, Igor Makhlin, Susan Dent, Benedicte Lefebvre, Joseph Carver, Jenica N. Upshaw, David DeRemer, Bonnie Ky, Avirup Guha, Yan Gong
Format: Article
Language:English
Published: Wiley 2023-06-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
breast cancer
cardio‐oncology
cardiotoxicity
CDK4/6 inhibitors
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.123.029361

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.123.029361

Similar Items